Rheumatoid Arthritis
Conditions
Brief summary
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Detailed description
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12, Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12, Percentage Of Participants Achieving Low Disease Activity (LDA) per Disease Activity Score-28 With C-Reactive Protein (DAS28-CRP) at Week 12, Percentage Of Participants Achieving Clinical Remission (CR) per DAS28 (CRP) at Week 12, Change from Baseline in DAS28 (CRP) at Week 12, Percentage Of Participants Achieving LDA per Clinical Disease Activity Index (CDAI) at Week 12, Percentage Of Participants Achieving CR per CDAI at Week 12
Interventions
Sponsors
AbbVie Deutschland GmbH & Co. KG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12, Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12, Percentage Of Participants Achieving Low Disease Activity (LDA) per Disease Activity Score-28 With C-Reactive Protein (DAS28-CRP) at Week 12, Percentage Of Participants Achieving Clinical Remission (CR) per DAS28 (CRP) at Week 12, Change from Baseline in DAS28 (CRP) at Week 12, Percentage Of Participants Achieving LDA per Clinical Disease Activity Index (CDAI) at Week 12, Percentage Of Participants Achieving CR per CDAI at Week 12 | — |
Countries
Czechia, Germany, Hungary, Poland, Slovakia, Spain
Outcome results
None listed